CL2011002859A1 - Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c. - Google Patents

Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c.

Info

Publication number
CL2011002859A1
CL2011002859A1 CL2011002859A CL2011002859A CL2011002859A1 CL 2011002859 A1 CL2011002859 A1 CL 2011002859A1 CL 2011002859 A CL2011002859 A CL 2011002859A CL 2011002859 A CL2011002859 A CL 2011002859A CL 2011002859 A1 CL2011002859 A1 CL 2011002859A1
Authority
CL
Chile
Prior art keywords
compounds
phenyl
alkyl
spironucleoside
compound
Prior art date
Application number
CL2011002859A
Other languages
English (en)
Spanish (es)
Inventor
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Hoof Steven Maurice Paula Van
Lili Hu
Abdellah Tahri
Original Assignee
Medivir Ab
Janssen Products Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab, Janssen Products Lp filed Critical Medivir Ab
Publication of CL2011002859A1 publication Critical patent/CL2011002859A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CL2011002859A 2009-05-14 2011-11-14 Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c. CL2011002859A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09160215 2009-05-14

Publications (1)

Publication Number Publication Date
CL2011002859A1 true CL2011002859A1 (es) 2012-07-20

Family

ID=40823307

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002859A CL2011002859A1 (es) 2009-05-14 2011-11-14 Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c.

Country Status (38)

Country Link
US (2) US8481510B2 (sr)
EP (2) EP2511282B1 (sr)
JP (2) JP5778135B2 (sr)
KR (1) KR101806837B1 (sr)
CN (1) CN102439024B (sr)
AP (1) AP2783A (sr)
AR (1) AR076579A1 (sr)
AU (1) AU2010247439B2 (sr)
BR (1) BRPI1010579A2 (sr)
CA (1) CA2760329C (sr)
CL (1) CL2011002859A1 (sr)
CO (1) CO6440533A2 (sr)
CR (1) CR20120297A (sr)
CY (2) CY1114081T1 (sr)
DK (2) DK2511282T3 (sr)
EA (1) EA022084B1 (sr)
EC (1) ECSP11011461A (sr)
ES (2) ES2411086T3 (sr)
HN (1) HN2011003014A (sr)
HR (2) HRP20130554T1 (sr)
IL (1) IL215955A (sr)
JO (1) JO3027B1 (sr)
ME (1) ME01478B (sr)
MX (1) MX2011012027A (sr)
MY (1) MY157018A (sr)
NI (1) NI201100197A (sr)
NZ (1) NZ596073A (sr)
PL (2) PL2430035T3 (sr)
PT (2) PT2430035E (sr)
RS (1) RS52822B (sr)
SG (1) SG175981A1 (sr)
SI (2) SI2511282T1 (sr)
SM (2) SMT201300078B (sr)
TW (1) TWI461432B (sr)
UA (1) UA105790C2 (sr)
UY (1) UY32642A (sr)
WO (1) WO2010130726A1 (sr)
ZA (1) ZA201108309B (sr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
US9006209B2 (en) 2010-11-10 2015-04-14 Janssen Products, Lp Uracyl spirooxetane nucleoside phosphoramidates
PL2638054T3 (pl) * 2010-11-10 2015-05-29 Janssen Products Lp Fosforoamidany nukleozydów uracylo-spirooksetanowych
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
AU2015252113B2 (en) * 2010-11-30 2017-05-04 Gilead Pharmasset Llc Compounds
ES2744587T3 (es) * 2011-04-13 2020-02-25 Gilead Sciences Inc Análogos de N-nucleósido de pirimidina 1-sustituidos para un tratamiento antiviral
US8980865B2 (en) * 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
HUE029038T2 (en) * 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
EP2940031B1 (en) 2013-03-08 2017-09-27 Nanjing Sanhome Pharmaceutical Co., Ltd. Nucleoside phosphoramidate compounds for use in the treatment of hcv
BR112015025766A2 (pt) 2013-04-12 2017-10-17 Achillion Pharmaceuticals Inc derivado de nucleosídeo altamente ativo para o tratamento de hcv
WO2014194826A1 (zh) * 2013-06-06 2014-12-11 南京圣和药业有限公司 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用
US20170165287A1 (en) * 2013-11-28 2017-06-15 Janssen Sciences Ireland Uc Crystal form of a nucleoside inhibitor of hcv
GEP20217282B (en) 2015-03-06 2021-08-10 Atea Pharmaceuticals Inc β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
CN110248951B (zh) 2017-02-01 2022-10-28 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
CN111836818B (zh) 2018-01-10 2023-10-31 纽科利制药公司 氨基磷(膦)酸缩醛和磷(膦)酸缩醛化合物
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
EP3999519A4 (en) 2019-07-17 2023-08-16 Nucorion Pharmaceuticals, Inc. CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021209427A1 (en) * 2020-04-14 2021-10-21 Janssen Sciences Ireland Unlimited Company Spirocyclic nucleoside analogues for the treatment of hepatitis e
EP4139319A4 (en) 2020-04-21 2024-06-19 Ligand Pharmaceuticals, Inc. BENZYLOXY-PHOSPH(ON)ATE COMPOUNDS
BR112023026356A2 (pt) 2021-06-17 2024-03-05 Atea Pharmaceuticals Inc Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1355916T1 (sl) * 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
CA2571079A1 (en) * 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
JP2009504704A (ja) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート
US7879815B2 (en) * 2006-02-14 2011-02-01 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
JO3027B1 (ar) 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان

Also Published As

Publication number Publication date
JP5778135B2 (ja) 2015-09-16
CR20120297A (es) 2012-10-25
TWI461432B (zh) 2014-11-21
SG175981A1 (en) 2011-12-29
EA022084B1 (ru) 2015-10-30
DK2511282T3 (da) 2014-07-07
AU2010247439A1 (en) 2011-12-01
ES2411086T3 (es) 2013-07-04
NI201100197A (es) 2012-05-28
HN2011003014A (es) 2014-06-30
PT2511282E (pt) 2014-07-11
EP2430035B1 (en) 2013-04-03
IL215955A (en) 2015-03-31
HRP20130554T1 (xx) 2013-07-31
SI2430035T1 (sl) 2013-08-30
NZ596073A (en) 2013-02-22
SMT201300078B (it) 2013-09-06
AU2010247439B2 (en) 2014-09-25
CN102439024B (zh) 2014-09-17
EP2430035A1 (en) 2012-03-21
PL2430035T3 (pl) 2013-08-30
ECSP11011461A (es) 2012-02-29
EA201171406A1 (ru) 2012-05-30
HRP20140605T1 (hr) 2014-09-26
PL2511282T3 (pl) 2014-09-30
AP2783A (en) 2013-10-31
RS52822B (sr) 2013-10-31
CA2760329C (en) 2017-10-31
HK1166326A1 (en) 2012-10-26
CY1114081T1 (el) 2016-07-27
US8481510B2 (en) 2013-07-09
US8933052B2 (en) 2015-01-13
CO6440533A2 (es) 2012-05-15
ES2477598T3 (es) 2014-07-17
CN102439024A (zh) 2012-05-02
US20130217648A1 (en) 2013-08-22
SI2511282T1 (sl) 2014-09-30
KR20120018355A (ko) 2012-03-02
US20120065156A1 (en) 2012-03-15
ME01478B (me) 2014-04-20
AP2011005958A0 (en) 2011-10-31
SMT201400085B (it) 2014-09-08
BRPI1010579A2 (pt) 2016-03-15
MY157018A (en) 2016-04-15
EP2511282A1 (en) 2012-10-17
ZA201108309B (en) 2013-04-24
MX2011012027A (es) 2012-02-28
CY1115383T1 (el) 2017-01-04
UA105790C2 (uk) 2014-06-25
EP2511282B1 (en) 2014-04-02
TW201100442A (en) 2011-01-01
JO3027B1 (ar) 2016-09-05
JP2012526764A (ja) 2012-11-01
DK2430035T3 (da) 2013-05-27
PT2430035E (pt) 2013-05-22
KR101806837B1 (ko) 2017-12-08
IL215955A0 (en) 2012-01-31
UY32642A (es) 2010-11-30
JP2015180692A (ja) 2015-10-15
CA2760329A1 (en) 2010-11-18
WO2010130726A1 (en) 2010-11-18
AR076579A1 (es) 2011-06-22

Similar Documents

Publication Publication Date Title
CO6440533A2 (es) Nucleósidos espiro oxetánicos uracílicos
UY32308A (es) Nucleótidos uracil ciclopropílicos
EA201201031A1 (ru) Ингибиторы вируса гепатита с
EA201390425A1 (ru) Ингибиторы hcv сериновой протеазы, полученные из макроциклического пролина
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
ECSP10010556A (es) Piridinas y pirazinas como inhibidores de pi3k
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
BR112013007696A2 (pt) composto, composição farmacêutica, usos do referido composto e da referida composição
UY32759A (es) Inhibidores del virus de la hepatitis c
PE20142186A1 (es) Derivados biciclicos de pirazinona
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER
ECSP077648A (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
AR088414A1 (es) Derivados sustituidos de indol
AR073037A1 (es) Derivados de enfumafungina, utiles en la inhibicionde (1,3)-beta-d-glucano sintasa
PE20141121A1 (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmaceuticos
AR080047A1 (es) Compuestos que liberan oxido nitrico para el tratamiento del dolor
CU20100179A7 (es) Piridinas y pirazinas como inhibidores de p13k
CU23948B1 (es) Compuestos y composiciones como moduladores de la actividad de tlr